PMID- 25904938
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150423
LR  - 20201001
IS  - 1687-9848 (Print)
IS  - 1687-9856 (Electronic)
IS  - 1687-9848 (Linking)
VI  - 2015
IP  - 1
DP  - 2015
TI  - Increased height standard deviation scores in response to growth hormone therapy 
      to near-adult height in older children with delayed skeletal maturation: results 
      from the ANSWER Program.
PG  - 1
LID - 10.1186/1687-9856-2015-1 [doi]
LID - 1
AB  - BACKGROUND: A primary goal of recombinant human growth hormone therapy (GHT) in 
      children is attaining normal adult height. In this study, children with growth 
      hormone deficiency (GHD) (including isolated idiopathic growth hormone deficiency 
      [IGHD] and multiple pituitary hormone deficiency [MPHD]), idiopathic short 
      stature (ISS), and Turner syndrome (TS) were evaluated for near-adult height 
      (NAH) and percent achieving NAH within the normal range after approximately 
      4 years of GHT. METHODS: Data from the American Norditropin(R) STUDIES: Web-Enabled 
      Research (ANSWER) Program were analyzed for NAH from age at treatment start (ATS) 
      (i.e., referral age as defined by age at enrollment in the study) to last clinic 
      visit using one of the following two criteria: 1) age >/=18 years, or 2) if male: 
      >/=16 years and height velocity (HV) <2 cm/year; if female: >/=15 years and HV 
      <2 cm/year. All patients had a baseline height standard deviation score 
      (HSDS) </= -2, and either GHD (n = 201), ISS (n = 19), or TS (n = 41). The main 
      outcome measures included HSDS and corrected HSDS (HSDS-target HSDS) in response 
      to GH treatment, and correlation of ATS with NAH HSDS. RESULTS: Mean (+/- SD) 
      chronological and bone ages at baseline were 14.0 +/- 2.1 years and 
      11.7 +/- 2.0 years, respectively, and mean GHT duration was 4.0 +/- 1.6 years. Mean 
      HSDS (baseline to NAH; GHD: -2.7 to -1.0; ISS: -2.8 to -1.4; TS: -3.0 to -1.8) 
      and mean corrected HSDS (baseline to NAH; GHD: -2.1 to -0.3; ISS: -2.1 to -0.6; 
      TS: -1.8 to -0.6) increased across diagnostic indications. Percentages of 
      patients reaching near-adult HSDS > -2 were GHD: 87.6%; ISS: 78.9%; TS: 65.8%. 
      Significant negative correlations were found between ATS and NAH HSDS when 
      analyzed by sex. CONCLUSIONS: Despite a relatively advanced childhood age, the 
      majority of GH-treated patients attained mean near-adult HSDS within the normal 
      range (HSDS > -2). Negative correlations of ATS with near-adult HSDS indicate 
      that an earlier age at treatment start would likely have resulted in greater 
      adult height achieved in both male and female patients.
FAU - Ross, Judith L
AU  - Ross JL
AD  - Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107 USA 
      ; Nemours/AI DuPont Hospital for Children, Wilmington, DE 19803 USA.
FAU - Lee, Peter A
AU  - Lee PA
AD  - Department of Pediatrics, Penn State College of Medicine, The Milton S. Hershey 
      Medical Center, Hershey, PA 17033 USA.
FAU - Gut, Robert
AU  - Gut R
AD  - Department of Clinical Development, Medical and Regulatory Affairs, Novo Nordisk, 
      Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536 USA.
FAU - Germak, John
AU  - Germak J
AD  - Department of Clinical Development, Medical and Regulatory Affairs, Novo Nordisk, 
      Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536 USA.
LA  - eng
PT  - Journal Article
DEP - 20150115
PL  - England
TA  - Int J Pediatr Endocrinol
JT  - International journal of pediatric endocrinology
JID - 101516111
PMC - PMC4405836
OTO - NOTNLM
OT  - Human growth hormone
OT  - Near-adult height
OT  - Short stature
EDAT- 2015/04/24 06:00
MHDA- 2015/04/24 06:01
PMCR- 2015/01/15
CRDT- 2015/04/24 06:00
PHST- 2014/08/11 00:00 [received]
PHST- 2014/12/16 00:00 [accepted]
PHST- 2015/04/24 06:00 [entrez]
PHST- 2015/04/24 06:00 [pubmed]
PHST- 2015/04/24 06:01 [medline]
PHST- 2015/01/15 00:00 [pmc-release]
AID - 362 [pii]
AID - 10.1186/1687-9856-2015-1 [doi]
PST - ppublish
SO  - Int J Pediatr Endocrinol. 2015;2015(1):1. doi: 10.1186/1687-9856-2015-1. Epub 
      2015 Jan 15.